Biocept, inc. announces the launch of its liquid biopsy test to detect trk biomarkers in the blood of patients diagnosed with cancer

Biocept, inc. announced the commercial availability of its target selector™ pan-trk assay for the detection of trk proteins. with the biocept assay, a simple blood sample can help inform physicians on the potential presence of ntrk fusions, which are actionable biomarkers that can be used to qualify patients for treatment with trk inhibitor therapies. with the launch of this new assay, biocept now offers 20 clia-certified liquid biopsy tests utilizing its target selector™ platform to determine the status of actionable solid tumor biomarkers.
BIOC Ratings Summary
BIOC Quant Ranking